Bellevue Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $248M | Sell |
|
|||||
|
2025
Q2 | $229M | Hold |
|
|||||
|
2025
Q1 | $201M | Hold |
|
|||||
|
2024
Q4 | $248M | Sell |
|
|||||
|
2024
Q3 | $215M | Sell |
|
|||||
|
2024
Q2 | $261M | Sell |
|
|||||
|
2024
Q1 | $284M | Sell |
|
|||||
|
2023
Q4 | $320M | Sell |
|
|||||
|
2023
Q3 | $291M | Sell |
|
|||||
|
2023
Q2 | $246M | Sell |
|
|||||
|
2023
Q1 | $265M | Sell |
|
|||||
|
2022
Q4 | $331M | Sell |
|
|||||
|
2022
Q3 | $303M | Buy |
|
|||||
|
2022
Q2 | $277M | Sell |
|
|||||
|
2022
Q1 | $283M | Sell |
|
|||||
|
2021
Q4 | $271M | Buy |
|
|||||
|
2021
Q3 | $288M | Sell |
|
|||||
|
2021
Q2 | $294M | Sell |
|
|||||
|
2021
Q1 | $318M | Sell |
|
|||||
|
2020
Q4 | $326M | Buy |
|
|||||
|
2020
Q3 | $317M | Buy |
|
|||||
|
2020
Q2 | $392M | Sell |
|
|||||
|
2020
Q1 | $282M | Sell |
|
|||||
|
2019
Q4 | $357M | Buy |
|
|||||
|
2019
Q3 | $297M | Sell |
|
|||||
|
2019
Q2 | $299M | Buy |
|
|||||
|
2019
Q1 | $1.78M | Sell |
|
|||||
|
2018
Q4 | $2.86M | Sell |
|
|||||
|
2018
Q3 | $5.11M | Sell |
|
|||||
|
2018
Q2 | $4.28M | Sell |
|
|||||
|
2018
Q1 | $4.45M | Sell |
|
|||||
|
2017
Q4 | $4.23M | Sell |
|
|||||
|
2017
Q3 | $3.43M | Buy |
|
|||||
|
2017
Q2 | $2.16M | Sell |
|
|||||
|
2017
Q1 | $2.94M | Sell |
|
|||||
|
2016
Q4 | $2.9M | Buy |
|
|||||
|
2016
Q3 | $2.94M | Hold |
|
|||||
|
2016
Q2 | $2.64M | Sell |
|
|||||
|
2016
Q1 | $2.57M | Buy |
|